Clinical trials: Coronavirus 2019
Covid19
Early Detection of COVID-19 Using Breath Analysis
EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY
- Trial name
- COVID-19 (NCT04602884)
- Testing
- Breath biopsy sampling using the ReCIVA Breath Sampler
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
SARS-CoV-2 Infection
Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
- Trial name
- PROTECT (NCT04834908)
- Testing
- Equine COVID-19 Antiserum, Standard of care
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Bharat Serums and Vaccines Limited
COVID-19
To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen
This is a Phase 3 study to assess the efficacy about therapeutic effect of inhaled CT-P63 and CT-P66 combination therapy to symptomatic patiemts with COVID-19 and overall safety.
- Trial name
- NCT05224856
- Sponsor
- Celltrion
MRSA Bloodstream Infection, MRSA Bacteremia
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)…
- Conditions
- MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
- Trial name
- NCT04597242
- Testing
- Exebacase
- Where
- 2 sites in United States
- Sponsor
- ContraFect
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
COVID-19, Coronavirus Disease 2019
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia.
- Conditions
- COVID-19, Coronavirus Disease 2019, Covid19, COVID-19 Pneumonia
- Trial name
- NCT04390217
- Testing
- LB1148
- Sponsor
- Leading BioSciences, Inc
Coronavirus Infection
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
The purpose of this study is to evaluate the safety and effectiveness of NasoVAX in preventing worsening of symptoms and hospitalization in patients with early COVID-19.
- Trial name
- NCT04442230
- Testing
- NasoVAX
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Altimmune, Inc.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Infection of Upper Respiratory Tract Caused by 2019-nCoV
SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
- Trial name
- NCT06042764
- Testing
- SA55 Injection
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea.
- Trial name
- NCT07089680
- Testing
- Nirmatrelvir/Ritonavir
- Where
- 7 sites in South Korea
- Volunteers
- 937 people
- Sponsor
- Pfizer
COVID 19
Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients
More cases of COVID-19 pandemic are being reported daily around the world. It is highly infectious and, over 7 million people have been infected and more than 400,000 people have died globally till this date.
- Trial name
- HCQ-COVID19 (NCT04437693)
- Testing
- Hydroxychloroquine
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
- Conditions
- Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections
- Trial name
- NCT07552779
- Testing
- Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
- Where
- Belgium
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality…
- Trial name
- NCT04547127
- Testing
- Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Instituto Grifols, S.A.
Pharmacokinetics, Safety Issues
Pharmacokinetics, Safety and Efficacy Study of GP30341 (GEROPHARM, Russia)
Pharmacokinetics, safety and efficacy study of GP30341, 200 mg capsules (GEROPHARM LLC, Russia) in healthy volunteers and patients with novel coronavirus infection 2019 (COVID-19) with a high risk of adverse outcome
- Conditions
- Pharmacokinetics, Safety Issues, Efficacy
- Trial name
- NCT05648799
- Testing
- GP30341 capsules 200 mg, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Geropharm
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
Coronavirus Disease 2019 (COVID-19)
Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
This is a Phase IV real-world, observational, non-interventional, prospective cohort study of adults vaccinated with AZD1222. The purpose of this study is to assess the safety and tolerability of AZD1222 in adults vaccinated in…
- Trial name
- COVID-19 (NCT04877743)
- Testing
- None (Observational study)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
- Trial name
- RESOLUTION (NCT04417257)
- Testing
- LAU-7b
- Where
- 29 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Laurent Pharmaceuticals Inc.